Ranbaxy Of India Seeks To Rebuild Relations With U.S. FDA
This article was originally published in PharmAsia News
Executive SummaryIndia's Ranbaxy Laboratories says in its annual report it plans to rebuild its strained relationship with U.S. FDA. Malvinder Mohan Singh, CEO and managing director of Ranbaxy, wrote in the report the company's focus is to be on resolving FDA's issues of compliance and good manufacturing practices. The company has plans to acquire FDA-approved manufacturing facilities to produce drugs once made at a pair of plants the FDA blacklisted. (Click here for more
You may also be interested in...
Janssen’s hemato-oncology success rolls on with impressive new overall survival data
Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.
Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business.